HIGHBuilt-inPipeline
DM199
“10-K Item 1A: 'Our prospects depend on the clinical and commercial success of our DM199 product candidate, which in turn depends upon many factors outside of our control.'”
DMAC · Concentration risk · 10-K extracted
DiaMedica Therapeutics (DMAC) concentration risks
Updated
The most significant concentration DiaMedica Therapeutics discloses is DM199, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: DiaMedica Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
contract development and manufacturing organizations (CDMOs)
“10-K Item 1A: 'We rely extensively on contract development and manufacturing organizations (CDMOs) for the manufacture and testing of DM199 under current good manufacturing procedures (cGMP).'”
HIGHOutside partyCounterparty
third-party IP licensor
“10-K Item 1A: 'We could lose important intellectual property rights that we currently license from a third party if we fail to comply with our obligations under the license agreement'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06DiaMedica's risk profile centers on a single clinical asset. The company states its prospects depend on the clinical and commercial success of DM199, a structural dependency that underlies the rest of the filing. Manufacturing is outsourced: DiaMedica relies extensively on contract development and manufacturing organizations (CDMOs) to produce and test DM199, adding an operational dependency layered on top of the single-asset risk. Separately, the company licenses important intellectual property from a third party and could lose those rights if it fails to meet its obligations under the license agreement. These three exposures are not diversifiable against one another — a manufacturing disruption or a licensing dispute would each directly impair the same program the company is already fully dependent on, so they compound rather than offset. There is no customer or geographic diversification disclosed to cushion any of this. For a clinical-stage biotech with one lead candidate, this is a familiar but binary risk shape: every exposure here is described at a high disclosed share, and none should be read as trivial.
For the engine’s reasoning on DMAC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| DMAC● | DiaMedica Therapeutics Inc. | 3 | 0 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.